Market news

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

ALAMEDA, Calif. , July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Penumbra (NYSE:PEN) received FDA clearance for its THUNDERBOLT computer-assisted vacuum thrombectomy system for acute ischemic stroke treatment. The THUNDER study reported strong safety and efficacy results for THUNDERBOLT in stroke care. A leading stroke center has begun using THUNDERBOLT in clinical practice, expanding its real world footprint. Penumbra, traded on the NYSE under ticker PEN, focuses on medical devices for neuro and vascular conditions, including stroke. The FDA clearance...

Penumbra (PEN) is back in focus after Novant Health reported successful use of its newly cleared THUNDERBOLT computer assisted vacuum thrombectomy system at a North Carolina comprehensive stroke center. See our latest analysis for Penumbra. At a share price of $318.73, Penumbra has seen a 1 year total shareholder return of 36.74%, while the 3 year and 5 year total shareholder returns of 3.46% and 19.72% suggest more moderate longer term progress as investors weigh new products like...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company's novel computer assisted vacuum thrombectomy (CAVT™) system, in stroke patients with emergent large vessel occlusion (ELVO). The data were presented this week during a late-breaking session at the Society of NeuroInterventional Surgery (SNIS) 23rd Annual Meeting.